Olugbeminiyi O. Fadeyi
Research Subjects
Olugbeminiyi O. Fadeyi has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Rob C. Oslund
Exploratory Science Center, Merck & Co., Inc., Cambridge, USA
18 shared publications Keun Ah Ryu
Merck Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States
9 shared publicationsTyler J. Bechtel
Merck Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States
7 shared publicationsCory H. White
Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA
6 shared publicationsErik C. Hett
Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA
6 shared publicationsTamara Reyes-Robles
Merck Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States
6 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Springer Nature in Nature
- Vol. 658 (8138) , 1319-1329
Proximity-guided graph learning reveals tumour-associated proximity antigens
The spatial organization of membrane proteins is an underexplored dimension of cell surface biology1,2. Spatial proximity shapes cellular function and therapeutic targetability2,3, yet efforts to identify tumour-associated antigens (TAAs) have largely focused on expression alone4. Here, we developed an industrialized surface protein proximity-mapping workflow to interrogate TAAs within their membrane microenvironments. Using this workflow, we generated 248 proximity maps across 12 receptor tyrosine kinases and 28 tumour cell systems. The resulting atlas enabled the development of MetaMap, a correlation-based analytical framework that defines spatial protein communities and infers conserved proximity relationships among non-targeted proteins, and establishes the concept of tumour-associated proximity antigens (TAPAs), a class of co-targets defined by disease-specific spatial proximity to TAAs rather than expression alone. Integrating these proximity-derived relationships within a multimodal prioritization framework, we identified and validated EGFR–CDCP1 as a TAA–TAPA pair that enhances tumour cell killing across therapeutic modalities. Together, this work advances disease-associated membrane proximity as a guiding principle for the design of precision multispecific therapeutics.
- 9 September 2026
- Published by Springer Nature in Nature
- Vol. 658 (8138) , 1319-1329
Open AccessProximity-guided graph learning reveals tumour-associated proximity antigens
The spatial organization of membrane proteins is an underexplored dimension of cell surface biology1,2. Spatial proximity shapes cellular function and therapeutic targetability2,3, yet efforts to identify tumour-associated antigens (TAAs) have largely focused on expression alone4. Here, we developed an industrialized surface protein proximity-mapping workflow to interrogate TAAs within their membrane microenvironments. Using this workflow, we generated 248 proximity maps across 12 receptor tyrosine kinases and 28 tumour cell systems. The resulting atlas enabled the development of MetaMap, a correlation-based analytical framework that defines spatial protein communities and infers conserved proximity relationships among non-targeted proteins, and establishes the concept of tumour-associated proximity antigens (TAPAs), a class of co-targets defined by disease-specific spatial proximity to TAAs rather than expression alone. Integrating these proximity-derived relationships within a multimodal prioritization framework, we identified and validated EGFR–CDCP1 as a TAA–TAPA pair that enhances tumour cell killing across therapeutic modalities. Together, this work advances disease-associated membrane proximity as a guiding principle for the design of precision multispecific therapeutics.
- Open Access
Proximity-Informed Graph Learning Defines Spatial Protein Communities for Tumor-Associated Proximity Antigen Discovery
The spatial organization of membrane proteins is an underexplored dimension of cell-surface biology. Spatial proximity shapes cellular function and therapeutic targetability, yet efforts to identify tumor-associated antigens (TAAs) have largely focused on expression alone. Here, we developed an industrialized surface-protein proximity mapping workflow to interrogate TAAs within their membrane microenvironments. In the process, we generated 248 proximity maps across 12 receptor tyrosine kinases (RTKs) and 28 tumor cell systems. This proximity atlas enabled two advances: first, MetaMap, a correlation-based analytical framework that defines spatial protein communities and infers non-targeted proximal proteins from reproducible proximity signatures; and second, tumor-associated proximity antigens (TAPAs), a conceptual class of co-targets defined by disease-specific spatial proximity to TAAs rather than expression alone. Applying these proximity-derived relationships within a multimodal prioritization framework, we identified and validated an EGFR×CDCP1 TAA-TAPA pair that enhanced tumor cell killing across therapeutic modalities. By integrating spatial organization with multimodal data, this work expands the design space for precision-guided therapeutic strategies.
Open AccessProximity-Informed Graph Learning Defines Spatial Protein Communities for Tumor-Associated Proximity Antigen Discovery
The spatial organization of membrane proteins is an underexplored dimension of cell-surface biology. Spatial proximity shapes cellular function and therapeutic targetability, yet efforts to identify tumor-associated antigens (TAAs) have largely focused on expression alone. Here, we developed an industrialized surface-protein proximity mapping workflow to interrogate TAAs within their membrane microenvironments. In the process, we generated 248 proximity maps across 12 receptor tyrosine kinases (RTKs) and 28 tumor cell systems. This proximity atlas enabled two advances: first, MetaMap, a correlation-based analytical framework that defines spatial protein communities and infers non-targeted proximal proteins from reproducible proximity signatures; and second, tumor-associated proximity antigens (TAPAs), a conceptual class of co-targets defined by disease-specific spatial proximity to TAAs rather than expression alone. Applying these proximity-derived relationships within a multimodal prioritization framework, we identified and validated an EGFR×CDCP1 TAA-TAPA pair that enhanced tumor cell killing across therapeutic modalities. By integrating spatial organization with multimodal data, this work expands the design space for precision-guided therapeutic strategies.
- 6 August 2024
- Published by Elsevier in Cell Chemical Biology
- Vol. 31 (8) , 1473-1489
Therapeutic potential of cis-targeting bispecific antibodies
- 6 August 2024
- Published by Elsevier in Cell Chemical Biology
- Vol. 31 (8) , 1473-1489
Therapeutic potential of cis-targeting bispecific antibodies
- 19 February 2024
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 14 (5) , 3482-3491
Near-Infrared Photoredox Catalyzed Fluoroalkylation Strategy for Protein Labeling in Complex Tissue Environments
- 19 February 2024
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 14 (5) , 3482-3491
Near-Infrared Photoredox Catalyzed Fluoroalkylation Strategy for Protein Labeling in Complex Tissue Environments
- Open Access
- 9 November 2023
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (11) , 1483-1484
In This Issue
- 9 November 2023
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (11) , 1483-1484
Open AccessIn This Issue
- 26 July 2023
- Published by Elsevier in Cell Chemical Biology
- Vol. 30 (10) , 1313-1322.e7
High-resolution photocatalytic mapping of SARS-CoV-2 spike interactions on the cell surface
- 26 July 2023
- Published by Elsevier in Cell Chemical Biology
- Vol. 30 (10) , 1313-1322.e7
High-resolution photocatalytic mapping of SARS-CoV-2 spike interactions on the cell surface
- 20 July 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (30) , 16289-16296
μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping
The characterization of ligand binding modes is a crucial step in the drug discovery process and is especially important in campaigns arising from phenotypic screening, where the protein target and binding mode are unknown at the outset. Elucidation of target binding regions is typically achieved by X-ray crystallography or photoaffinity labeling (PAL) approaches; yet, these methods present significant challenges. X-ray crystallography is a mainstay technique that has revolutionized drug discovery, but in many cases structural characterization is challenging or impossible. PAL has also enabled binding site mapping with peptide- and amino-acid-level resolution; however, the stoichiometric activation mode can lead to poor signal and coverage of the resident binding pocket. Additionally, each PAL probe can have its own fragmentation pattern, complicating the analysis by mass spectrometry. Here, we establish a robust and general photocatalytic approach toward the mapping of protein binding sites, which we define as identification of residues proximal to the ligand binding pocket. By utilizing a catalytic mode of activation, we obtain sets of labeled amino acids in the proximity of the target protein binding site. We use this methodology to map, in vitro, the binding sites of six protein targets, including several kinases and molecular glue targets, and furthermore to investigate the binding site of the STAT3 inhibitor MM-206, a ligand with no known crystal structure. Finally, we demonstrate the successful mapping of drug binding sites in live cells. These results establish μMap as a powerful method for the generation of amino-acid- and peptide-level target engagement data.
- 20 July 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (30) , 16289-16296
μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping
The characterization of ligand binding modes is a crucial step in the drug discovery process and is especially important in campaigns arising from phenotypic screening, where the protein target and binding mode are unknown at the outset. Elucidation of target binding regions is typically achieved by X-ray crystallography or photoaffinity labeling (PAL) approaches; yet, these methods present significant challenges. X-ray crystallography is a mainstay technique that has revolutionized drug discovery, but in many cases structural characterization is challenging or impossible. PAL has also enabled binding site mapping with peptide- and amino-acid-level resolution; however, the stoichiometric activation mode can lead to poor signal and coverage of the resident binding pocket. Additionally, each PAL probe can have its own fragmentation pattern, complicating the analysis by mass spectrometry. Here, we establish a robust and general photocatalytic approach toward the mapping of protein binding sites, which we define as identification of residues proximal to the ligand binding pocket. By utilizing a catalytic mode of activation, we obtain sets of labeled amino acids in the proximity of the target protein binding site. We use this methodology to map, in vitro, the binding sites of six protein targets, including several kinases and molecular glue targets, and furthermore to investigate the binding site of the STAT3 inhibitor MM-206, a ligand with no known crystal structure. Finally, we demonstrate the successful mapping of drug binding sites in live cells. These results establish μMap as a powerful method for the generation of amino-acid- and peptide-level target engagement data.
- 15 June 2023
- Published by Springer Nature in Nature Chemistry
- Vol. 15 (9) , 1267-1275
An electroaffinity labelling platform for chemoproteomic-based target identification
Target identification involves deconvoluting the protein target of a pharmacologically active, small-molecule ligand, a process that is critical for early drug discovery yet technically challenging. Photoaffinity labelling strategies have become the benchmark for small-molecule target deconvolution, but covalent protein capture requires the use of high-energy ultraviolet light, which can complicate downstream target identification. Thus, there is a strong demand for alternative technologies that allow for controlled activation of chemical probes to covalently label their protein target. Here we introduce an electroaffinity labelling platform that leverages the use of a small, redox-active diazetidinone functional group to enable chemoproteomic-based target identification of pharmacophores within live cell environments. The underlying discovery to enable this platform is that the diazetidinone can be electrochemically oxidized to reveal a reactive intermediate useful for covalent modification of proteins. This work demonstrates the electrochemical platform to be a functional tool for drug-target identification.
- 15 June 2023
- Published by Springer Nature in Nature Chemistry
- Vol. 15 (9) , 1267-1275
An electroaffinity labelling platform for chemoproteomic-based target identification
Target identification involves deconvoluting the protein target of a pharmacologically active, small-molecule ligand, a process that is critical for early drug discovery yet technically challenging. Photoaffinity labelling strategies have become the benchmark for small-molecule target deconvolution, but covalent protein capture requires the use of high-energy ultraviolet light, which can complicate downstream target identification. Thus, there is a strong demand for alternative technologies that allow for controlled activation of chemical probes to covalently label their protein target. Here we introduce an electroaffinity labelling platform that leverages the use of a small, redox-active diazetidinone functional group to enable chemoproteomic-based target identification of pharmacophores within live cell environments. The underlying discovery to enable this platform is that the diazetidinone can be electrochemically oxidized to reveal a reactive intermediate useful for covalent modification of proteins. This work demonstrates the electrochemical platform to be a functional tool for drug-target identification.
- Open Access
- 17 May 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (26) , 7327-7333
Targeted proximity-labelling of protein tyrosines via flavin-dependent photoredox catalysis with mechanistic evidence for a radical–radical recombination pathway
Flavin-based photocatalysts such as riboflavin tetraacetate (RFT) serve as a robust platform for light-mediated protein labelling via phenoxy radical-mediated tyrosine–biotin phenol coupling on live cells. To gain insight into this coupling reaction, we conducted detailed mechanistic analysis for RFT-photomediated activation of phenols for tyrosine labelling. Contrary to previously proposed mechanisms, we find that the initial covalent binding step between the tag and tyrosine is not radical addition, but rather radical–radical recombination. The proposed mechanism may also explain the mecha-nism of other reported tyrosine-tagging approaches. Competitive kinetics experiments show that phenoxyl radicals are generated with several reactive intermediates in the proposed mechanism—primarily with the excited riboflavin-photocatalyst or singlet oxygen—and these multiple pathways for phenoxyl radical generation from phenols increase the likelihood of radical–radical recombination.
- 17 May 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (26) , 7327-7333
Open AccessTargeted proximity-labelling of protein tyrosines via flavin-dependent photoredox catalysis with mechanistic evidence for a radical–radical recombination pathway
Flavin-based photocatalysts such as riboflavin tetraacetate (RFT) serve as a robust platform for light-mediated protein labelling via phenoxy radical-mediated tyrosine–biotin phenol coupling on live cells. To gain insight into this coupling reaction, we conducted detailed mechanistic analysis for RFT-photomediated activation of phenols for tyrosine labelling. Contrary to previously proposed mechanisms, we find that the initial covalent binding step between the tag and tyrosine is not radical addition, but rather radical–radical recombination. The proposed mechanism may also explain the mecha-nism of other reported tyrosine-tagging approaches. Competitive kinetics experiments show that phenoxyl radicals are generated with several reactive intermediates in the proposed mechanism—primarily with the excited riboflavin-photocatalyst or singlet oxygen—and these multiple pathways for phenoxyl radical generation from phenols increase the likelihood of radical–radical recombination.
- 12 January 2023
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (1) , 1-2
In This Issue, Volume 14, Issue 1
- 12 January 2023
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (1) , 1-2
In This Issue, Volume 14, Issue 1